Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
Date:8/5/2011

 We have completed Phase 2b clinical studies of lesinurad and continue to advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor, RDEA3170, is currently in preclinical development. BAY 86-9766 (RDEA119) is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare. BAY 86-9766 (RDEA119) is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib and a Phase 1/Phase 2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad (RDEA594), BAY 86-9766 (RDEA119) and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the head
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Ardea Biosciences to Present at Upcoming Investor Conferences
2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
4. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
5. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
6. Ardea Biosciences Prices Public Offering of Common Stock
7. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
8. Ardea Biosciences to Present at Two Upcoming Investor Conferences
9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
10. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
11. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain ... 100x better detail than the industry standard. But ... microscopy methods, it needed another medium to measure its ... of reference because it represents the highest standard of ... earliest discovery days of Ultralight Histology was to reverse ...
(Date:5/4/2015)... , May 4, 2015   Intrexon Corporation ... first quarter 2015 financial results after the market closes ... conference call that day at 5:30 PM ET to ... The conference call may be accessed by ... to join the "Intrexon Conference Call."  Participants may also ...
(Date:5/1/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... priced an underwritten registered offering of 3,900,000 shares of ... share, and granted the underwriters in the offering a ... shares of its common stock. The gross proceeds to ... to close on May 6, 2015, subject to customary ...
(Date:5/1/2015)... , May 1, 2015 Albany Molecular ... William S. Marth , AMRI,s President and Chief ... Merrill Lynch 2015 Health Care Conference on Wednesday, May ... live audio webcast of the presentation can be accessed ... The webcast will be archived for ...
Breaking Biology Technology:Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2
... ... in Prima BioMed Ltd (ASX:PRR), an Australian Securities Exchange-listed oncology biotechnology company. KTA ... Investors, LLC on the transaction. A copy of Prima BioMed Ltd,s public announcement ... ...
... ... Dr. Rebecca Fitzgerald, known among her medical colleagues as the "Sculptra guru" here in the ... at this year,s 4 day SDEF Cosmetic Dermatology Seminar held in Santa Monica, Ca. ... Los Angeles, Ca (PRWEB) ...
... multiple times a day can be difficult for patients to ... 1 to 7 percent of the dose is actually absorbed ... PhD, director of the Laboratory for Biomaterials and Drug Delivery ... can gradually dispense a constant amount of medication to the ...
Cached Biology Technology:KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd 2Looking Older Than You Are May Have Little to Do With Wrinkles 2Looking Older Than You Are May Have Little to Do With Wrinkles 3A drug-dispensing contact lens 2
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... 2013 - BGI Health and ACIBADEM Healthcare Group ... Molecular Biology, signed a Memorandum of Understanding (MoU) ... to Turkey and improving Turkish reproductive healthcare. This ... technologies in the areas of Monogenic disorders, personalized ...
... do woolly mammoths wandering around the ancient spruce ... with predicting how species could respond to climate ... Center for Environmental Science,s Appalachian Laboratory, along with ... University of California-Merced, have received a three-year, $670,000 ...
... do nerve cells -- which can each be up to ... falling apart? Axons, the long, cable-like projections on neurons, ... molecular building block of the cell skeleton. The finding, which ... was reported in the April 10 issue of Neuron ...
Cached Biology News:BGI Health forms partnership with ACIBADEM hospital on genetic disease testing 2Scientists look to ancient past to better predict how species may respond climate change 2Scientists learn what makes nerve cells so strong 2
Laminin beta-1/gamma-1 (612C10)...
HSV 1 IgM...
100 ug affinity purified rabbit anti-JIP-1 polyclonal antibody. Reacts with mouse and rat. Perform well in Western blotting. Other applications have not been tested. Storage Temperature: -20C Shi...
Epstein-Barr Virus (EBV) (EBNA-1)...
Biology Products: